Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Stifel Reinstates Buy on nLight, Announces $18 Price Target

Stifel Reinstates Buy on nLight, Announces $18 Price Target

Stifel analyst Ruben Roy reinstates nLight (NASDAQ:LASR) with a Buy and announces $18 price target.

byBenzinga Newsdesk

November 4, 2022

1 minute read

Stifel analyst Ruben Roy reinstates nLight (NASDAQ:LASR) with a Buy and announces $18 price target.

Morgan Stanley Maintains Equal-Weight on Root. Price Adjusts to $37.26

By Benzinga Newsdesk

August 15, 8:44 AM

Morgan Stanley analyst Michael Phillips maintains Root (NASDAQ:ROOT) with a Equal-Weight.Price Adjusts to $37.26

ROOT

CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs

By Vandana Singh

January 30, 11:17 AM

CureVac N.V. (NASDAQ:CVAC) announced extended preliminary data from ongoing Phase 1 programs in COVID-19 and seasonal flu conducted in collaboration with GSK…

CVAC

News

CapStar Announces Expansion To Asheville

By Benzinga Newsdesk

July 8, 11:39 AM

CapStar Bank, a subsidiary of CapStar Financial Holdings (NASDAQ:CSTR), today announced its entry into Asheville. Martin Nesbitt has joined CapStar as Asheville Market President and will begin building a team of

CSTR

Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering?

By Neil Dennis

January 18, 1:48 PM

Pharmaceuticals prices are already up in 2024: Can inflation-beating hikes be justified?

BMY

Stifel Reinstates Buy on nLight, Announces $18 Price Target

Related Posts

Morgan Stanley Maintains Equal-Weight on Root. Price Adjusts to $37.26

CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs

CapStar Announces Expansion To Asheville

Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering?